Investors in Krystal Biotech, Inc. (KRYS) need to pay close attention to the stock based on moves in the options market lately. That is because the Feb. 21, 2025 $100 Callhad some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could a ...

PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and c ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

Krystal Biotech (KRYS) announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response (measured using RECIST v1.1 criteria) of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung ...

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced tod ...

Krystal Biotech, Inc. (KRYS) announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating rare respiratory diseases.Shares of the company were down 7.3% on Dec. 12 following the announcement of the news.KB407 is being developed in a phase I study for the treatment of cystic fibrosis (CF), while KB408 is being developed in a phase I study for treating alpha-1 antitrypsin deficiency (AATD).The la ...

A month has gone by since the last earnings report for Krystal Biotech, Inc. (KRYS) . Shares have added about 6.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Krystal Biotech due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Krystal Q3 Earnings and Sales Top Estim ...

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences: Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gable ...

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning ...

Krystal Biotech (KRYS) reported third-quarter earnings per share of 91 cents, which beat the Zacks Consensus Estimate of 84 cents. In the year-ago quarter, the company incurred a loss of 67 cents per share.Revenues totaled $83.8 million, which beat the Zacks Consensus Estimate of $83 million. Revenues came in solely from the sales of Vyjuvek. In the year-ago quarter, revenues amounted to $8.6 million.Shares of Krystal have surged 37.8% year to date against the industry’s decline of 3.8%.Image Source: Zacks ...